Impaired Glucose Tolerance
7
Pipeline Programs
4
Companies
4
Clinical Trials
4
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
3
4
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Small Molecule
2100%
+ 3 programs with unclassified modality
On Market (4)
Approved therapies currently available
Competitive Landscape
4 companies ranked by most advanced pipeline stage
DS
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
TakedaPioglitazone
GSKRamipril
TakedaVoglibose
Daiichi SankyoAspirin
Clinical Trials (4)
Total enrollment: 6,428 patients across 4 trials
Actos Now for Prevention of Diabetes (ACT NOW)
Start: Jan 2004Est. completion: Apr 2010602 patients
Phase 3Completed
The DREAM (Diabetes Reduction Assessment With Ramipril and Rosiglitazone Medication) Trial
Start: Jul 2001Est. completion: Oct 20065,000 patients
Phase 3Completed
Voglibose Tablets 0.2 / OD Tablets 0.2 Special Drug Use Surveillance "Long-term Use in Patients With Impaired Glucose Tolerance"
Start: Nov 2009Est. completion: Aug 2013742 patients
N/ACompleted
Cardiovascular Disease (CVD) Risk and Prevention in Early Glucose Intolerance
Start: May 2005Est. completion: May 201184 patients
N/ACompleted
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
3 late-stage (Phase 3) programs — potential near-term approvals
4 companies competing in this space